Decision Resources has a new report that says cancer mAbs and immunotherapies will grow rapidly from its revenues of $1.1 B in 2012 to reach $9 B in 2022. Growth will be heavily fueled by anti-CTLA-4 and the newer anti-PD-1/PD-L1 immune checkpoint inhibitors. Companies that will really benefit from this include BMS, Roche, AZ and Merck who are expected to garner up to 85% of this share. Combination therapies with these drugs and chemotherapeutic agents will also add to the impact. See PharmaTimes.
Posted by Bruce Lehr July 8th 2014.